Valuation: BioNTech SE

Market Cap 19.84B 22.15B 18.25B 16.53B 30.9B 2,103B 31.48B 218B 87.35B 1,106B 83.12B 81.35B 3,489B P/E 2026 *
-13.5x
P/E 2027 * -14.7x
Enterprise Value 8.74B 9.76B 8.04B 7.28B 13.62B 927B 13.87B 95.87B 38.48B 487B 36.62B 35.84B 1,537B EV / Sales 2026 *
4.92x
EV / Sales 2027 * 5.61x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.08%
1 week+0.06%
Current month-10.31%
1 month-10.31%
3 months-5.04%
6 months-14.77%
Current year-7.38%
1 week 85
Extreme 85
90.32
1 month 85
Extreme 85
100.02
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
374.58
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 61 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Chairman 56 2008-06-01
Director/Board Member 69 2008-06-01
Director/Board Member 65 2017-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/9/26 Sell

Chief Executive Officer

-36,209 0.0150%
10/7/26 Sell

Chief Executive Officer

-24,000 0.0099%
10/6/26 Sell

Chief Executive Officer

-21,000 0.0087%
Change 5-day change 1-year change 3-year change Capi.($)
-1.08%+0.06%-15.76%-5.45% 22.39B
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.04%+12.64%+83.62% 56.16B
+0.53%+2.55%+13.90%+104.77% 54.16B
-2.81%-4.31%+23.50%+50.90% 45.33B
-0.33%-1.93%+20.15%+98.45% 42.25B
+0.55%+2.31%+224.97%+942.56% 40.78B
+3.27%+47.40%+110.44%+94.92% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average -0.02%+4.19%+45.87%+146.99% 41.51B
Weighted average by Cap. -0.04%+3.41%+45.92%+153.19%

Financials

2026 *2027 *
Net sales 1.78B 1.98B 1.63B 1.48B 2.77B 188B 2.82B 19.47B 7.82B 99B 7.44B 7.28B 312B 1.8B 2.01B 1.65B 1.5B 2.8B 191B 2.85B 19.71B 7.91B 100B 7.53B 7.37B 316B
Net income -1.46B -1.63B -1.34B -1.21B -2.27B -155B -2.31B -15.99B -6.42B -81.28B -6.11B -5.98B -256B -1.28B -1.43B -1.18B -1.07B -2B -136B -2.04B -14.07B -5.65B -71.51B -5.37B -5.26B -226B
Net Debt -11.1B -12.39B -10.21B -9.25B -17.29B -1,176B -17.61B -122B -48.86B -619B -46.5B -45.51B -1,952B -9.75B -10.89B -8.97B -8.13B -15.19B -1,034B -15.48B -107B -42.95B -544B -40.87B -40B -1,715B
Projected Income Statement - Annual - BioNTech SE
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
26-10-30 $88.17 -1.08% 631,838
26-10-29 $89.13 +1.30% 692,715
26-10-28 $87.99 +1.07% 870,559
26-10-27 $87.06 +0.23% 1,076,779
26-10-26 $86.86 -1.42% 1,406,944
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - BioNTech SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
78.97EUR
Average target price
104.42EUR
Spread / Average Target
+32.24%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BioNTech SE
  1. Stock Market
  2. Stocks
  3. BNTX Stock